S Schülke1, A Flaczyk1, L Vogel2, N Gaudenzio3, I Angers4, B Löschner5, S Wolfheimer1, I Spreitzer5, S Qureshi4,6, M Tsai3, S Galli3, S Vieths1, S Scheurer1. 1. Vice President's Research Group 1: Molecular Allergology, Paul-Ehrlich-Institut, Langen, Germany. 2. Division of Allergology, Paul-Ehrlich-Institut, Langen, Germany. 3. Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. 4. Research Institute of the McGill University Health Center, Montréal, QC, Canada. 5. Division of Microbiology, Paul-Ehrlich-Institut, Langen, Germany. 6. Department of Medicine, McGill University, Montréal, QC, Canada.
Abstract
BACKGROUND: Monophosphoryl lipid A (MPLA), a nontoxic TLR4 ligand derived from lipopolysaccharide (LPS), is used clinically as an adjuvant in cancer, hepatitis, and malaria vaccines and in allergen-specific immunotherapy. Nevertheless, its cell-activating effects have not been analyzed in a comprehensive direct comparison including a wide range of different immune cells. Therefore, the objective of this study was the side-by-side comparison of the immune-modulating properties of MPLA and LPS on different immune cells. METHODS: Immune-activating properties of MPLA and LPS were compared in human monocytes and mast cells (MCs), a mouse endotoxin shock model (ESM), and mouse bone marrow (BM)-derived myeloid dendritic cells (mDCs), T cells (TCs), B cells, and MCs. RESULTS: In a mouse in vivo ESM and a human ex vivo monocyte activation test (MAT), MPLA induced the same cytokine secretion pattern as LPS (ESM: IL-6, IL-12, TNF-α; MAT: IL-1β, IL-6, TNF-α), albeit at lower levels. Mouse mDCs and ex vivo isolated B cells stimulated with MPLA required a higher threshold to induce TRIF-dependent cytokine secretion (IL-1β, IL-6, IL-10, and TNF-α) than did LPS-stimulated cells. In mDC:DO11.10 CD4 TC cocultures, stimulation with MPLA, but not with LPS, resulted in enhanced OVA-specific IL-4 and IL-5 secretion from DO11.10 CD4 TCs. Unexpectedly, in both human and mouse MCs, MPLA, unlike LPS, did not elicit secretion of pro-inflammatory cytokines. CONCLUSIONS: Compared to LPS, MPLA induced a qualitatively similar, but less potent pro-inflammatory immune response, but was unable to activate human or mouse MCs.
BACKGROUND: Monophosphoryl lipid A (MPLA), a nontoxic TLR4 ligand derived from lipopolysaccharide (LPS), is used clinically as an adjuvant in cancer, hepatitis, and malaria vaccines and in allergen-specific immunotherapy. Nevertheless, its cell-activating effects have not been analyzed in a comprehensive direct comparison including a wide range of different immune cells. Therefore, the objective of this study was the side-by-side comparison of the immune-modulating properties of MPLA and LPS on different immune cells. METHODS: Immune-activating properties of MPLA and LPS were compared in human monocytes and mast cells (MCs), a mouse endotoxin shock model (ESM), and mouse bone marrow (BM)-derived myeloid dendritic cells (mDCs), T cells (TCs), B cells, and MCs. RESULTS: In a mouse in vivo ESM and a human ex vivo monocyte activation test (MAT), MPLA induced the same cytokine secretion pattern as LPS (ESM: IL-6, IL-12, TNF-α; MAT: IL-1β, IL-6, TNF-α), albeit at lower levels. Mouse mDCs and ex vivo isolated B cells stimulated with MPLA required a higher threshold to induce TRIF-dependent cytokine secretion (IL-1β, IL-6, IL-10, and TNF-α) than did LPS-stimulated cells. In mDC:DO11.10 CD4 TC cocultures, stimulation with MPLA, but not with LPS, resulted in enhanced OVA-specific IL-4 and IL-5 secretion from DO11.10 CD4 TCs. Unexpectedly, in both human and mouse MCs, MPLA, unlike LPS, did not elicit secretion of pro-inflammatory cytokines. CONCLUSIONS: Compared to LPS, MPLA induced a qualitatively similar, but less potent pro-inflammatory immune response, but was unable to activate human or mouse MCs.
Authors: Antonio Hernandez; Naeem K Patil; Cody L Stothers; Liming Luan; Margaret A McBride; Allison M Owen; Katherine R Burelbach; David L Williams; Edward R Sherwood; Julia K Bohannon Journal: Pharmacol Res Date: 2019-11-02 Impact factor: 7.658
Authors: Liming Luan; Naeem K Patil; Yin Guo; Antonio Hernandez; Julia K Bohannon; Benjamin A Fensterheim; Jingbin Wang; Yaomin Xu; Perenlei Enkhbaatar; Ryan Stark; Edward R Sherwood Journal: Sci Rep Date: 2017-01-05 Impact factor: 4.379
Authors: Stefan Schülke; Lothar Vogel; Ann-Christine Junker; Kay-Martin Hanschmann; Adam Flaczyk; Stefan Vieths; Stephan Scheurer Journal: J Immunol Res Date: 2016-06-01 Impact factor: 4.818